Sermorelin Vial

Sermorelin (GRF 1-29) is a synthetic analogue of growth hormone–releasing hormone (GHRH), comprising the N-terminal 29 amino acids of the native peptide. It is commonly utilised in laboratory research involving GHRH-related pathways, receptor interactions, and peptide signalling systems.

Sermorelin is a peptide fragment derived from GHRH. In controlled research environments, it is used as a model compound in studies involving peptide structure, receptor-associated pathways, and experimental biological systems.

Chemical reference information: CAS number: 86168-78-7; Molecular formula: C₁₄₉H₂₄₆N₄₄O₄₂S; Molecular weight: 3357.93 g/mol. These reference identifiers describe the formulation; the batch-specific analytical record identifies the supplied material.

Reference conditions for unreconstituted research material are −20°C with moisture and direct light excluded. Use the storage instructions on the supplied batch record for the actual presentation, and record any change of physical state or storage conditions.

Where laboratory preparation is required, use an appropriate validated solvent and aseptic peptide-handling procedure. Solvent compatibility, final concentration, and post-preparation storage depend on the specific formulation and experimental protocol. The catalog strength is the compound amount, not the concentration of a prepared solution.

NORVEXA Bioscience batch documentation can be requested using the printed reference and lot number. Review identity, analytical purity, presentation, and handling specifications before including a material in a laboratory workflow.

Sermorelin 5 mg is offered as a NORVEXA research vial. The selected strength refers to the compound content of this vial reference. Request the matching batch record for identity, analytical specifications, and presentation details.

Reference conditions for unreconstituted research material are −20°C with moisture and direct light excluded. Use the storage instructions on the supplied batch record for the actual presentation, and record any change of physical state or storage conditions.

Where laboratory preparation is required, use an appropriate validated solvent and aseptic peptide-handling procedure. Solvent compatibility, final concentration, and post-preparation storage depend on the specific formulation and experimental protocol. The catalog strength is the compound amount, not the concentration of a prepared solution.

NORVEXA Bioscience batch documentation can be requested using the printed reference and lot number. Review identity, analytical purity, presentation, and handling specifications before including a material in a laboratory workflow.

CAS number

86168-78-7

Molecular formula

C₁₄₉H₂₄₆N₄₄O₄₂S

Molecular weight

3357.93 g/mol

Include the printed batch reference when requesting your certificate of analysis. The record applies to the batch supplied to your laboratory.